Bavarian Nordic has announced Tarja Stenvall, currently a Sanofi executive, will become President and CEO effective October 15, succeeding Paul Chaplin. Stenvall has led Sanofi’s €10 billion diabetes and cardiovascular franchise as SVP and Head of Global Franchise. Chaplin’s departure was previously signaled in March, and he had led Bavarian Nordic for more than a decade, joining in 1999 and rising to CEO in 2014. The CEO transition is a material governance event for the company, which is known for vaccine and immuno-oncology platforms. Stenvall’s background in large-scale franchise leadership suggests a shift toward execution discipline and portfolio scaling. For investors, management continuity on clinical and commercial priorities will be watched closely over the next quarters. Leadership changes at vaccine-focused biopharma firms often influence alliance negotiations, manufacturing roadmap decisions, and how aggressively companies pursue new indications or partners.